Antibody–drug conjugates: Recent advances in payloads

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads with efficient killing, show great clinical therapeutic value. The ADCs' payloads play a key role in determining the efficacy of ADC drugs and thus have attracted great attention in the field. An ideal ADC payload should possess sufficient toxicity, low immunogenicity, high stability, and modifiable functional groups. Common ADC payloads include tubulin inhibitors and DNA damaging agents, with tubulin inhibitors accounting for more than half of the ADC drugs in clinical development. However, due to clinical limitations of traditional ADC payloads, such as inadequate efficacy and the…

• NN
  National Natural Science Foundation of China

  Award: 82073318
• UF
  U.S. Food and Drug Administration
• SP
  Sichuan Province Science and Technology Support Program

  Award: 2019YFS0003
• FR
  Fundamental Research Funds for the Central Universities

  Awards: 0082604151345, SCU2022D025